NEJM Publishes Ianalumab Study for Sjögren's Disease Treatment
Start here
The New England Journal of Medicine has published a study of ianalumab in patients with Sjögren's disease, a chronic autoimmune disorder affecting moisture-producing glands. The article appears in the journal's October 22, 2026 issue (Volume 395, Issue 16, pages 1585-1599) under DOI 10.1056/NEJMoa2601088. Ianalumab, an antibody-based therapy, has been under investigation for this condition, which currently has limited targeted treatment options. The publication marks the peer-reviewed record of the trial's findings, though details of the results and any regulatory implications for the drug's approval in Sjögren's disease are not addressed here and remain open questions.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- nejm.orgPickIanalumab for the Treatment of Patients with Sjögren’s Disease
The New England Journal of Medicine published a study of ianalumab for the treatment of patients with Sjögren's disease. The article appears in Volume 395, Issue 16, pages 1585-1599, DOI 10.1056/NEJMoa2601088.
Heat trend for this story
Not enough continuous observation yet to draw a trend.